These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

414 related items for PubMed ID: 29096861

  • 1. Current insights into the German Lipoprotein Apheresis Registry (GLAR) - Almost 5 years on.
    Schettler VJJ, Neumann CL, Peter C, Zimmermann T, Julius U, Roeseler E, Heigl F, Grützmacher P, Blume H, Scientific Board of GLAR for the German Apheresis Working Group.
    Atheroscler Suppl; 2017 Nov; 30():50-55. PubMed ID: 29096861
    [Abstract] [Full Text] [Related]

  • 2. The German Lipoprotein Apheresis Registry (GLAR) - almost 5 years on.
    Schettler VJJ, Neumann CL, Peter C, Zimmermann T, Julius U, Roeseler E, Heigl F, Grützmacher P, Blume H, Vogt A, Scientific Board of GLAR for the German Apheresis Working Group.
    Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):44-49. PubMed ID: 28233268
    [Abstract] [Full Text] [Related]

  • 3. Efficacy, safety, and tolerability of long-term lipoprotein apheresis in patients with LDL- or Lp(a) hyperlipoproteinemia: Findings gathered from more than 36,000 treatments at one center in Germany.
    Heigl F, Hettich R, Lotz N, Reeg H, Pflederer T, Osterkorn D, Osterkorn K, Klingel R.
    Atheroscler Suppl; 2015 May; 18():154-62. PubMed ID: 25936320
    [Abstract] [Full Text] [Related]

  • 4. First data from the German Lipoprotein Apheresis Registry (GLAR).
    Schettler VJ, Neumann CL, Peter C, Zimmermann T, Julius U, Roeseler E, Heigl F, Ramlow W, Blume H, Scientific Board of GLAR for the German Apheresis Working Group.
    Atheroscler Suppl; 2015 May; 18():41-4. PubMed ID: 25936303
    [Abstract] [Full Text] [Related]

  • 5. The German Lipoprotein Apheresis Registry-Summary of the ninth annual report.
    Schettler VJJ, Peter C, Zimmermann T, Julius U, Roeseler E, Schlieper G, Heigl F, Grützmacher P, Löhlein I, Klingel R, Hohenstein B, Ramlow W, Vogt A, Scientific Board of GLAR for the German Apheresis Working Group.
    Ther Apher Dial; 2022 Dec; 26 Suppl 1():81-88. PubMed ID: 36468337
    [Abstract] [Full Text] [Related]

  • 6. Lipoprotein apheresis is an optimal therapeutic option to reduce increased Lp(a) levels.
    Schettler VJJ, Neumann CL, Peter C, Zimmermann T, Julius U, Hohenstein B, Roeseler E, Heigl F, Grützmacher P, Blume H, Klingel R, Vogt A, Scientific Board of GLAR for the German Apheresis Working Group.
    Clin Res Cardiol Suppl; 2019 Apr; 14(Suppl 1):33-38. PubMed ID: 30838552
    [Abstract] [Full Text] [Related]

  • 7. The German Lipoprotein Apheresis Registry-Summary of the eleventh annual report.
    Schettler VJJ, Selke N, Jenke S, Zimmermann T, Schlieper G, Bernhardt W, Heigl F, Grützmacher P, Löhlein I, Klingel R, Hohenstein B, Ramlow W, Vogt A, Julius U, Scientific Board of GLAR for the German Apheresis Working Group.
    Atherosclerosis; 2024 Nov; 398():118601. PubMed ID: 39342791
    [Abstract] [Full Text] [Related]

  • 8. Current insights into the German lipoprotein apheresis standard: PCSK9-inhibitors, lipoprotein apheresis or both?
    Schettler VJJ, Ringel J, Jacob S, Julius U, Klingel R, Heigl F, Roeseler E, Grützmacher P, German Society of Nephrology (DGfN) and the Foundation of German Centers of Nephrology (DN).
    Atheroscler Suppl; 2017 Nov; 30():44-49. PubMed ID: 29096860
    [Abstract] [Full Text] [Related]

  • 9. Rationale and design of MultiSELECt: A European Multicenter Study on the Effect of Lipoprotein(a) Elimination by lipoprotein apheresis on Cardiovascular outcomes.
    Hohenstein B, Julius U, Lansberg P, Jaeger B, Mellwig KP, Weiss N, Graehlert X, Roeder I, Ramlow W.
    Atheroscler Suppl; 2017 Nov; 30():180-186. PubMed ID: 29096835
    [Abstract] [Full Text] [Related]

  • 10. Current view: indications for extracorporeal lipid apheresis treatment.
    Schettler V, Neumann CL, Hulpke-Wette M, Hagenah GC, Schulz EG, Wieland E, German Apheresis Working Group.
    Clin Res Cardiol Suppl; 2012 Jun; 7(Suppl 1):15-9. PubMed ID: 22528134
    [Abstract] [Full Text] [Related]

  • 11. Impact of the German Lipoprotein Apheresis Registry (DLAR) on therapeutic options to reduce increased Lp(a) levels.
    Schettler VJ, Neumann CL, Peter C, Zimmermann T, Julius U, Roeseler E, Heigl F, German Apheresis Working Group.
    Clin Res Cardiol Suppl; 2015 Apr; 10(Suppl 1):14-20. PubMed ID: 25652812
    [Abstract] [Full Text] [Related]

  • 12. Lipoprotein apheresis in Germany - Still more commonly indicated than implemented. How can patients in need access therapy?
    Heigl F, Pflederer T, Klingel R, Hettich R, Lotz N, Reeg H, Schettler VJJ, Roeseler E, Grützmacher P, Hohenstein B, Julius U.
    Atheroscler Suppl; 2019 Dec; 40():23-29. PubMed ID: 31818446
    [Abstract] [Full Text] [Related]

  • 13. Actual situation of lipoprotein apheresis in Saxony in 2013.
    Emmrich U, Hohenstein B, Julius U.
    Atheroscler Suppl; 2015 May; 18():215-25. PubMed ID: 25936329
    [Abstract] [Full Text] [Related]

  • 14. Lipoprotein(a)-apheresis in the light of new drug developments.
    Vogt A.
    Atheroscler Suppl; 2017 Nov; 30():38-43. PubMed ID: 29096859
    [Abstract] [Full Text] [Related]

  • 15. Lipoprotein apheresis for Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease--Additional particular aspects of the Pro(a)LiFe multicenter trial.
    Klingel R, Heibges A, Fassbender C.
    Atheroscler Suppl; 2015 May; 18():35-40. PubMed ID: 25936302
    [Abstract] [Full Text] [Related]

  • 16. Prevention of cardiovascular complications in patients with Lp(a)-hyperlipoproteinemia and progressive cardiovascular disease by long-term lipoprotein apheresis according to German national guidelines.
    Klingel R, Heibges A, Fassbender C, Pro(a)LiFe-Study Group.
    Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):38-43. PubMed ID: 28185214
    [Abstract] [Full Text] [Related]

  • 17. Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study.
    Leebmann J, Roeseler E, Julius U, Heigl F, Spitthoever R, Heutling D, Breitenberger P, Maerz W, Lehmacher W, Heibges A, Klingel R, Pro(a)LiFe Study Group*.
    Circulation; 2013 Dec 17; 128(24):2567-76. PubMed ID: 24056686
    [Abstract] [Full Text] [Related]

  • 18. Detailed description of the cardiovascular situation in patients who have started lipoprotein apheresis treatment.
    Schampera S, Fischer S, Weiss N, Julius U.
    Atheroscler Suppl; 2015 May 17; 18():209-14. PubMed ID: 25936328
    [Abstract] [Full Text] [Related]

  • 19. Most significant reduction of cardiovascular events in patients undergoing lipoproteinapheresis due to raised Lp(a) levels - A multicenter observational study.
    Schatz U, Tselmin S, Müller G, Julius U, Hohenstein B, Fischer S, Bornstein SR.
    Atheroscler Suppl; 2017 Nov 17; 30():246-252. PubMed ID: 29096845
    [Abstract] [Full Text] [Related]

  • 20. Lipoprotein apheresis efficacy, challenges and outcomes: A descriptive analysis from the UK Lipoprotein Apheresis Registry, 1989-2017.
    Pottle A, Thompson G, Barbir M, Bayly G, Cegla J, Cramb R, Dawson T, Eatough R, Kale V, Neuwirth C, Nicholson K, Payne J, Scott J, Soran H, Walji S, Watkins S, Weedon H, Nath Datta DB.
    Atherosclerosis; 2019 Nov 17; 290():44-51. PubMed ID: 31563836
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.